Empirical Ventures, a UK-based deeptech investor, has announced a £10 million fundraise dedicated to backing 'venture scientists'—technically trained founders building hard technology solutions across biotech, materials science, quantum, and advanced manufacturing. The funding arrives amid a broader surge in European deeptech investment, with Tech.eu data recording over 60 venture-backed deeptech deals valued at €1.2 billion across the continent in recent years.

For UK founders in physics, chemistry, engineering, and life sciences, this development signals an important shift: specialized deeptech capital is increasingly available, but competition for it is intensifying. This article breaks down what Empirical Ventures' expansion means for your fundraising strategy, how to position yourself within this ecosystem, and the broader landscape reshaping UK early-stage deeptech funding.

Who Is Empirical Ventures and Why Does This Matter?

Empirical Ventures was founded to address a structural gap in UK venture capital: most traditional VCs lack the technical depth to evaluate deeptech businesses, particularly those requiring 5–10 year development timelines and substantial capital commitments. Empirical's model centres on backing 'venture scientists'—founders with PhDs or equivalent domain expertise who combine scientific rigour with entrepreneurial ambition.

The £10 million raise allows Empirical to expand its portfolio into new sectors and provides patient capital for companies that conventional VCs might view as too risky or slow-growth. This is not seed-stage funding in the traditional sense; Empirical typically backs companies with proven scientific proof-of-concept and a credible path to commercialisation.

Why this matters now: UK deeptech founders have historically faced a funding gap between government grants (Innovate UK, Research England) and institutional venture rounds. Empirical and peers like Begbies Travers deeptech analysis show that UK deeptech deployment lags European peers in speed and scale. Germany, France, and the Netherlands have invested heavily in deeptech ecosystems through public-private partnerships. Empirical's fresh capital helps the UK compete.

The Broader European Deeptech Investment Surge

According to Tech.eu's venture data, European deeptech investment has accelerated over the past 18–24 months. The firm recorded 60+ deeptech deals valued at €1.2 billion, spanning biotech, climate tech, advanced materials, quantum computing, and semiconductors. Key trends:

• Geopolitical urgency: The UK and EU recognize deeptech as strategic. China's advances in semiconductors and rare earth processing have spurred government backing for European alternatives. UK policy responses include the Advanced Research and Invention Agency (ARIA) and expanded Innovate UK support.
• Longer capital cycles: Traditional VCs are increasingly willing to deploy patient capital. Empirical's £10M raise reflects confidence that UK investors now accept 7–10 year hold periods for deeptech.
• Cross-border mobility: Deeptech founders increasingly pitch to pan-European syndicates rather than local VCs. A Cambridge biotech researcher might raise from investors in Berlin, Amsterdam, and London simultaneously.
• Climate and sustainability focus: ~40% of recent European deeptech deals involve climate mitigation, carbon removal, or clean energy. UK founders in these verticals face less scepticism about market timing than in previous cycles.

Tech.eu's reporting also highlights that successful European deeptech raises typically involve:

1. Clear scientific IP (usually patented or under patent application)
2. Pilot customer or government contract validation
3. Experienced scientific advisory board
4. Clear regulatory pathway (especially for biotech and medtech)

Empirical Ventures' focus on venture scientists directly addresses these criteria.

What Empirical Ventures' £10M Means for UK Founders

Expanded Cheque Sizes and Patient Capital

Empirical's new capital likely means larger follow-on investment rounds for existing portfolio companies and capital for new bets that traditional VCs would avoid. Typical deeptech companies require:

• Seed/pre-seed: £200k–£1M (often government grants + angel investors)
• Series A: £2M–£5M (proof-of-concept to first customer)
• Series B: £10M–£30M (scaling production or clinical trials)

Empirical's fund likely targets Series A and B cheques, meaning they can support companies over 3–5 year development phases without pressure for premature exit or pivot.

Access to Scientific Networks and Expertise

Deeptech VCs add value beyond capital. Empirical's team typically includes scientists, engineers, and operators who have built or sold deeptech companies. They provide:

• Scientific advisory services and protocol review
• Regulatory pathway guidance (FDA, EMA, MHRA for biotech; HSE for safety-critical materials)
• Customer introductions in industry (aerospace, pharma, energy)
• PhD recruitment support
• Patent and IP strategy counsel

For UK founders, access to this network is critical. Many deeptech exits (e.g., Synthego's acquisition by Alphabet, Oxford Nanopore's public listing) were preceded by deep operational support from specialist investors.

Signals for Other Investors

Empirical's investment is a signal to institutional LPs, corporate venture arms, and strategic acquirers that a company has credible deeptech credentials. This is especially valuable for founders fundraising from:

• Corporates: Pharma, aerospace, energy companies seeking external innovation pipelines
• Government bodies: Innovate UK, UK Space Agency, Advanced Research and Invention Agency
• Strategic acquirers: Large industrials scouting acquisition targets

An Empirical backing is, in effect, third-party validation of your scientific and commercial rigor.

How to Position Yourself for Deeptech Funding in 2026

Build Credible Scientific Proof-of-Concept

Empirical and peers do not invest in pre-scientific founders. Before pitching:

• Publish peer-reviewed results or have clear IP (patent application filed at UK Intellectual Property Office)
• Demonstrate reproducibility and scale (move beyond proof-of-principle to proof-of-concept)
• Have co-founders or advisors with complementary PhDs and industry credibility

UK founders benefit from:

• Innovate UK grants: Competition rounds for R&D (typically £50k–£500k) that can fund initial IP and prototyping
• SEIS/EIS tax relief: When raising from angel investors, ensure compliance so investors get 50% tax relief (SEIS) or 30% (EIS). This makes your round more attractive.
• Research councils: EPSRC and BBSRC offer proof-of-concept funding (£150k–£1M) for university spinouts

Application tip: Frame your science in commercial language. Investors like Empirical understand molecular biology, but they need to hear about addressable market, customer pain, and regulatory pathway alongside your novel mechanism.

Identify Your Regulatory and Customer Validation Path

Deeptech founders must articulate:

• For biotech/medtech: Are you targeting small molecule (SMD), biologic (MHRA pathway), or device (Class I–III under MDR)? Do you have a clinical advisor? When is your first-in-human study planned?
• For advanced materials/manufacturing: Who is your anchor customer? Have you signed an LOI or pilot contract?
• For quantum/semiconductors: What is your differentiation vs. incumbents? What is the pathway to revenue (IP licensing, hardware sales, services)?

Empirical and similar investors will assess regulatory risk carefully. Clear pathways reduce perceived risk and increase investment likelihood.

Assemble an Experienced Advisory Board

Deeptech investors weight scientific credentials and market credibility heavily. Your advisors should include:

• At least one proven scientist/founder who has scaled a company or exited successfully
• Industry veterans with P&L responsibility in your target market
• Regulatory or clinical experts (especially for life sciences)

UK founders can tap the Association of the Governors and Senior Managers (AGSM) networks, university spinout offices, and Innovate UK portfolios for experienced advisors. Many retired pharma, aerospace, or energy executives advise for equity and meaningful engagement rather than fees.

Leverage Government Support Strategically

Before approaching Empirical or similar VCs, de-risk your company using public capital:

• Innovate UK: Grants and loan funding for R&D and commercialisation (no equity dilution). Announcement of successful Innovate UK grant strengthens investor confidence.
• Advanced Research and Invention Agency (ARIA): High-risk, high-reward funding for transformative research (up to £20M for moonshot-scale projects).
• Catapult centres: High Value Manufacturing, Satellite Applications, and others offer subsidised access to equipment, testing facilities, and mentorship.
• Regional funds: Scotland, Wales, and Northern Ireland offer tailored deeptech funding (e.g., Scottish Enterprise, Welsh Government Innovation Investment Fund).

Combining £500k in Innovate UK funding with a £2M Series A from Empirical creates a strong capital structure and validates your business thesis across public and private funders.

Competitive Landscape: Who Else Is Backing UK Deeptech?

Empirical Ventures is not alone. Other specialized deeptech investors active in the UK include:

• Pale Blue Dot Energy: Climate and energy-focused deeptech fund
• Plural: Pre-seed and seed funding for hard tech founders
• BGF (Business Growth Fund): Growth equity for proven deeptech companies
• Corporate venture arms: Unilever Ventures, Shell Ventures, GSK Ventures, Roche Ventures backing relevant startups

European peers like Breakthrough Energy (Europe), HV Capital (Berlin), and Ada Ventures (pan-European, inclusive) also back UK deeptech companies, creating a broader funding ecosystem.

However, competition for capital is fierce. TechEurope reports that European deeptech deal completion rates have tightened: investors are backing fewer, larger bets rather than many small ones. This means founders need stronger scientific credentials, clearer customer validation, and experienced teams to win capital.

Key Metrics to Track for Your Deeptech Fundraise

If you are pursuing deeptech funding, monitor these metrics to gauge readiness:

Practical Fundraising Checklist for Deeptech Founders

Before pitching Empirical Ventures or similar investors, ensure you have:

• ✓ Technical co-founder with PhD or equivalent deep technical domain experience
• ✓ Patented or patent-pending IP (file at UK Intellectual Property Office or PCT route)
• ✓ Peer-reviewed publication or strong technical report demonstrating novel approach
• ✓ Letter of Intent (LOI) or pilot contract from a credible customer or strategic partner
• ✓ Regulatory pathway document (biotech/medtech: outline FDA/MHRA strategy; hard-tech: identify relevant standards)
• ✓ Advisory board with 3–5 members including at least one successful founder or industry executive
• ✓ Companies House registration and VAT registration (basic legal infrastructure)
• ✓ SEIS/EIS advance documentation (if raising from angels pre-Series A)
• ✓ Clear 5-year financial model showing path to profitability or scale exit
• ✓ Competitive landscape analysis showing why your technology is defensible

Forward-Looking Analysis: The UK Deeptech Funding Landscape in 2026 and Beyond

Momentum and Headwinds

Empirical Ventures' £10M raise is a positive signal, but UK deeptech faces structural challenges:

Tailwinds:

• Government support is expanding (ARIA, Innovate UK scaling, regional funds)
• Corporate venture interest is high as pharma, aerospace, and energy companies seek external innovation
• UK talent pool is world-class (Cambridge, Oxford, Imperial, UCL produce top scientists)
• Regulatory frameworks are becoming clearer (MHRA post-Brexit guidance, ESG reporting standards creating demand for climate tech)

Headwinds:

• European competition is fierce; German and Dutch governments are aggressively funding deeptech
• Capital intensity is rising; Series B and C rounds need £20M+, limiting LP pool to large, patient investors
• Timeline to exit is long (7–12 years typical), testing founder and investor conviction
• Talent recruitment is competitive; US and China offer higher salaries for researchers and engineers

Emerging Opportunities for Founders

Several thematic areas are likely to attract growing capital in 2026–2028:

• Climate tech and energy transition: Battery materials, carbon capture, heat tech, sustainable chemicals. UK has strong academic IP and government backing (Net Zero Innovation Portfolio).
• Advanced biologics and therapeutics: CRISPR, cell therapy, protein engineering. UK biotech remains world-leading; Empirical's raise signals confidence in this space.
• Semiconductor and quantum: UK Chip Act (forthcoming) likely to drive government funding for semiconductor design and manufacturing. Quantum computing startups attract strategic corporate interest.
• Advanced manufacturing: Additive manufacturing, precision engineering, composites. Often lower capital intensity than biotech; faster to revenue.
• Sustainability and circular economy: Materials recovery, waste-to-product, industrial symbiosis. Growing corporate and government demand.

Structural Shifts in Deeptech Funding

Looking forward, expect:

• More syndication across geographies: UK founders will increasingly raise from European syndicates rather than purely domestic VCs. Familiarize yourself with German (Speedinvest, HV Capital), French (Vala Capital, Ada Ventures), and Dutch (Anterra) deeptech investors.
• More government co-investment: Innovate UK and regional funds will anchor rounds, with VCs co-investing. This reduces VC risk and increases available capital.
• Longer founder journeys: Expect to raise multiple grants before Series A. Founders who successfully navigate Innovate UK → Series A → Series B with government and VC support will outpace those seeking pure VC capital early.
• Increased focus on sustainability credentials: Beyond climate tech, all deeptech companies will need ESG credentials to attract institutional LPs. Green patents, regulatory compliance, and diversity metrics matter.

Recommendations for Founders Planning 2026–2028 Fundraises

If you are building deeptech and seeking capital, consider this sequencing:

1. Months 1–6: Build scientific IP, publish or patent, recruit advisors. Apply for Innovate UK, ARIA, or Catapult support if eligible.
2. Months 6–12: Generate first customer validation (LOI, pilot, signed contract). Secure government grant or loan. Use time and capital to prove technical and commercial thesis.
3. Months 12–18: Pitch Series A to Empirical, Plural, or similar specialists. Leverage government backing as proof of concept.
4. Post-Series A: Use capital to scale team, accelerate product development, expand customer base. Plan Series B for 24–36 months post-Series A, potentially targeting larger generalist funds or strategics.

This path de-risks your company, strengthens your investor narrative, and aligns with how Empirical and peers evaluate deeptech today.

Conclusion: What's Next for UK Deeptech Founders

Empirical Ventures' £10 million fundraise is a meaningful milestone for UK deeptech. It signals that patient capital is available, that specialist investors are scaling, and that the ecosystem is maturing. For founders with credible science, market insight, and experienced teams, the window for deeptech funding is wide open.

The competition, however, is real. Founders must combine scientific rigour with commercial clarity, leverage government support, and build advisory boards and customer validation that reduce investor risk. Those who do will find capital from Empirical, peers, and strategic partners increasingly available.

The next 12–24 months will likely see more specialist deeptech funds raise and deploy capital across the UK and Europe. First-mover founders—those who de-risk now and pitch strategically—will attract the best capital and talent. If you are building hard tech, the time is now.

Key resources for your next steps: Start with Innovate UK to explore grant opportunities, register your IP at the UK IPO, and build your advisory board. Then map investors like Empirical Ventures and similar funds into your fundraising plan. European accelerators like Plug and Play and sector-specific networks (e.g., Biotech UK, Made in the UK for advanced manufacturing) can help you connect with capital and customer early.